Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GamaMabs Pharma SA

http://www.gamamabs.com/

Latest From GamaMabs Pharma SA

Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

Deals Business Strategies

GamaMabs’ Glyco-Engineered Murlentamab Shows Promise in Colorectal, Gynecological Cancers

Murlentamab Phase II results indicate its potential for use in combination with chemotherapy or other immunological agents, to target AMHRII-expressing tumors.

Clinical Trials ImmunoOncology

Start-Up Previews, April 2014

This Month's Profile Group, Antibodies Evolve, features profiles of GamaMabs, Numab, and Zebra Biologics. Plus these Start-Ups Across Health Care: CoolCore Biomedical Technologies, EBS Technologies, and Xeltis.

BioPharmaceutical Medical Device

GamaMabs Pharma SA

GamaMabs Pharma SA is one of the latest contenders aiming to boost the biological activity of antibodies by altering their attached sugar groups. The company, located in Toulouse, France, was founded in June 2013 to develop therapeutic antibody treatments for gynecologic cancers, using core technologies licensed from the French Laboratories for Biotechnologies.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
UsernamePublicRestriction

Register